ProQR Therapeutics NV (ProQR Therapeutics NV) EV-to-EBITDA : -2.23 (As of Apr. 25, 2024)

ProQR Therapeutics NV EV-to-EBITDA Chart

ProQR Therapeutics NV Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA		Get a 7-Day Free Trial					-6.45	-3.12	-6.87	-3.70	-2.01

ProQR Therapeutics NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-3.70	-0.91	-0.34	0.01	-2.01

Competitive Comparison of ProQR Therapeutics NV's EV-to-EBITDA

For the Biotechnology subindustry, ProQR Therapeutics NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProQR Therapeutics NV's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's EV-to-EBITDA falls into.

ProQR Therapeutics NV EV-to-EBITDA Calculation

ProQR Therapeutics NV's EV-to-EBITDA for today is calculated as:

ProQR Therapeutics NV's current Enterprise Value is $57.85 Mil.
ProQR Therapeutics NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV  (NAS:PRQR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

ProQR Therapeutics NV's PE Ratio for today is calculated as:

ProQR Therapeutics NV's share price for today is $2.01.
ProQR Therapeutics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.377.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

ProQR Therapeutics NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description